Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Rectal Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Prednisone 54Radiotherapy 52Docetaxel 52Leuprolide 48Goserelin 47bicalutamide 45enzalutamide 30acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27Androgen Antagonists 27Flutamide 24Triptorelin Pamoate 22apalutamide 19Gonadotropin-Releasing Hormone 18Abiraterone Acetate 18abiraterone 16Radiation 15Zoledronic Acid 14Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 12Prednisolone 11luprolide acetate gel depot 10darolutamide 10cabazitaxel 9Radiosurgery 9Standard of Care 8Specimen Handling 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 8Estramustine 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Neoplasms × ferumoxtran-10 × Clear all
NCT04261777 2026-04-28

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V.

Phase 3 Terminated
172 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00622973 2011-10-12

USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

Insel Gruppe AG, University Hospital Bern

Phase 3 Completed
130 enrolled
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡